Published On: Wed, Oct 19th, 2016

Current Price Targets For Illumina, Inc. (NASDAQ:ILMN)


Recently stock market analysts have updated their consensus ratings on shares of Illumina, Inc. (NASDAQ:ILMN).

Most recent broker ratings

10/13/2016 – Illumina, Inc. had its “buy” rating reiterated by analysts at Argus. They now have a USD 170 price target on the stock.

10/11/2016 – Illumina, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 142 price target on the stock.

10/11/2016 – Illumina, Inc. had its “market perform” rating reiterated by analysts at Wells Fargo. They now have a USD 137.5 price target on the stock.

10/11/2016 – Illumina, Inc. had its “neutral” rating reiterated by analysts at BTIG Research.

10/11/2016 – Illumina, Inc. was downgraded to “sell” by analysts at Janney Montgomery Scott. They now have a USD 125 price target on the stock.

10/11/2016 – Illumina, Inc. was downgraded to “neutral” by analysts at Citigroup. They now have a USD 140 price target on the stock.

10/11/2016 – Illumina, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 160 price target on the stock.

10/11/2016 – Illumina, Inc. had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 155 price target on the stock.

10/11/2016 – Illumina, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 135 price target on the stock.

08/22/2016 – Illumina, Inc. was downgraded to “neutral” by analysts at CL King.

07/27/2016 – Illumina, Inc. had its “neutral” rating reiterated by analysts at Mizuho. They now have a USD 148 price target on the stock.

07/27/2016 – Illumina, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 180 price target on the stock.

07/14/2016 – Illumina, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 161 price target on the stock.

07/05/2016 – Illumina, Inc. was downgraded to “underweight” by analysts at Morgan Stanley. They now have a USD 110 price target on the stock.

05/04/2016 – Illumina, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 160 price target on the stock.

Illumina, Inc. has a 50 day moving average of 169.54 and a 200 day moving average of 155.73. The stock’s market capitalization is 21.29B, it has a 52-week low of 127.10 and a 52-week high of 196.47.

The share price of the company (NASDAQ:ILMN) was up +2.83% during the last trading session, with a high of 149.32 and the volume of Illumina, Inc. shares traded was 2517647.

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.